| Literature DB >> 29760959 |
Hagen Frickmann1,2, Thomas Köller2, Ralf Matthias Hagen3, Klaus-Peter Ebert4, Martin Müller5, Werner Wenzel1,5, Renate Gatzer5, Ulrich Schotte6, Alfred Binder6, Romy Skusa2, Philipp Warnke2, Andreas Podbielski2, Christian Rückert7, Bernd Kreikemeyer2.
Abstract
INTRODUCTION: We assessed the molecular epidemiology of multidrug-resistant bacteria colonizing or infecting war-injured patients from Libya and Syria who were treated at the Bundeswehr hospitals Hamburg and Westerstede, Germany.Entities:
Keywords: Libya; Syria; multidrug-resistant; next-generation sequencing; rep-PCR; typing; war injuries
Year: 2018 PMID: 29760959 PMCID: PMC5944420 DOI: 10.1556/1886.2018.00002
Source DB: PubMed Journal: Eur J Microbiol Immunol (Bp) ISSN: 2062-509X
Assessed Libyan and Syrian patients and their accommodation in the Bundeswehr Hospitals of Hamburg and Westerstede
| Wards and patient rooms of the Libyan patients in the Bundeswehr Hospital of Hamburg from admission to isolation of the last newly detected multidrug-resistant isolate (22 days) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Patient ID | Sex | Age (years) | Main diagnosis | Ward HBG-1-ITS, room 1 | Ward HBG-2, room 1 | Ward HBG-2, room 2 | Ward HBG-2, room 3 | Ward HBG-2, room 4 |
| HBG-L1 | Male | 38 | War trauma (multiple) | Day 1–2 | Day 2–18 | Day 18–22 | n.a. | n.a. |
| HBG-L2 | Male | 26 | War trauma (multiple) | Day 1–3 | Day 3–22 | n.a. | n.a. | n.a. |
| HBG-L3 | Male | 35 | War trauma (multiple) | n.a. | Day 1–2 | n.a. | Day 2–22 | n.a. |
| HBG-L4 | Male | 32 | War trauma (multiple) | n.a. | n.a. | Day 13–18 | n.a. | Day 1–13 and 18–22 |
Patients were discharged prior to the isolation of the last newly detected multidrug-resistant isolate (32 days).
Patient was discharged prior to the isolation of the last newly detected multidrug-resistant isolate (69 days).
Isolated Enterobacteriaceae with resistance against 3rd generation methoxyimino cephalosporins or carbapenems, nonfermentative Gram-negative rod-shaped bacteria, and methicillin-resistant Staphylococcus aureus (MRSA) from Libyan and Syrian patients.
| Isolates from Libyan patients | ||||||||
|---|---|---|---|---|---|---|---|---|
| Enterobacteriaceae with resistance against 3rd generation methoxyimino cephalosporins or carbapenems | ||||||||
| Patient I.D. | Sample I.D. | Species | Isolation site | Day of isolation | Nosocomial | In rep-PCR 95% identical with | In NGS-based MLST[ | Match NGS vs. rep-PCR |
| HBG-L1 | 2 | Rectum | Day 2 | No | ||||
| HBG-L1 | 3 | Rectum | Day 10 | Yes | 14 (WEST-L3), 48 (WEST-S6), 54 (WEST-S6) | 14 (WEST-L3)[ | 14 (WEST-L3) | |
| HBG-L1 | 4 | Rectum | Day 10 | Yes | ||||
| HBG-L1 | 6 | Colostomy | Day 22 | Yes | 33 (WEST-S2)[ | |||
| HBG-L2 | 8 | Inguinal skin | Day 1 | No | 18 (HBG-L4)[ | |||
| HBG-L2 | 10 | Inguinal skin | Day 1 | No | 48 (WEST-S6), 54 (WEST-S6), 77 (HBG-S4) | |||
| HBG-L2 | 12 | Inguinal skin | Day 10 | Yes | ||||
| HBG-L3 | 16 | Inguinal skin | Day 1 | No | 27 (room 1 HBG-2), 28 (room 3 HBG-2) | 27 (room 1 HBG-2)[ | 27 (room 1 HBG-2), 28 (room 3 HBG-2) | |
| HBG-L3 | 17 | Perineal skin | Day 1 | No | None | |||
| HBG-L4 | 18 | Inguinal skin | Day 16 | Yes | 20 (room 4 HBG-2), 26 (room 4 HBG-2) | 8 (HBG-L2)[ | 20 (room 4 HBG-2), 26 (room 4 HBG-2) | |
| WEST-L2 | 13 | Inguinal skin | Day 1 | No | None | |||
| West-L3 | 14 | External fixator of the left thigh | Day 1 | No | 3 (HBG-L1), 48 (WEST-S6), 54 (WEST-S6) | 3 (HBG-L1)[ | 3 (HBG-L1) | |
| West-L4 | 15 | Inguinal skin | Day 1 | No | ||||
a Completely identical based on MLST
(a) identical based on MLST but not all markers complete due to lack of coverage.
b Identical based on ANI (>= 99.9%)
(b) highly similar based on ANI (>= 99.5%, < 99.9%).
Isolated Enterobacteriaceae with resistance against 3rd generation methoxyimino cephalosporins or carbapenems, and nonfermentative Gram-negative rod-shaped bacteria, from the environment of Libyan patients at the Bundeswehr Hospital of Hamburg.
| Isolates from the environment of Libyan patients at the Bundeswehr Hospital of Hamburg | ||||||||
|---|---|---|---|---|---|---|---|---|
| Enterobacteriaceae with resistance against 3rd generation methoxyimino cephalosporins or carbapenems | ||||||||
| Ward | Room number | Sample I.D. | Species | Isolation site | Day of isolation | In rep-PCR 95% identical with | In NGS-based MLST[ | NGS-based MLST type |
| HBG-2 | Room 4 | 20 | hands | Day 11 | 18 (HBG-L4), 26 (room 4 HBG-2) | 8 (HBG-L2)[ | 18 (HBG-L4), 26 (room 4 HBG-2)[ | |
| HBG-2 | Room 3 | 21 | hands | Day 11 | None | |||
| HBG-2 | Room 4 | 26 | handle of a bag | Day 11 | 18 (HBG-L4), 20 (room 4 HBG-2) | 8 (HBG-L2)[ | 18 (HBG-L4), 20 (room 4 HBG-2) | |
| HBG-2 | Room 1 | 27 | hands and beard | Day 11 | 16 (HBG-L3), 28 (room 3 HBG-2) | 16 (HBG-L3)[ | 16 (HBG-L3), 28 (room 3 HBG-2) | |
| HBG-2 | Room 3 | 28 | walking frame | Day 11 | 16 (HBG-L3), 27 (room 1 HBG-2), | 16 (HBG-L3)[ | 16 (HBG-L3), 27 (room 1 HBG-2), | |
a Completely identical based on MLST
(a) identical based on MLST but not all markers found/complete due to lack of coverage.
b Identical based on ANI (>= 99.9%)
(b) highly similar based ANI (>= 99.5%, < 99.9%).
Detection of ESBL genes in Enterobacteriaceae that tested positive or not determined for ESBL by ABCD testing.
| Isolates from Libyan patients (n=13) | 10[ | 6[ | 10 (76.9%) | 1 (7.7%) | ||
| Isolates from the environment of Libyan patients at the Bundeswehr Hospital of Hamburg (n=5) | 5[ | 4[ | 5 (100%) | |||
| Isolates from Syrian patients (n=29) | 15[ | 5[ | 26 (89.7%) | 1 (3.4%) |
aDistribution of sequences: bla without exception.
bDistribution of sequences: bla without exception.
cDistribution of sequences: bla in 14 instances, not resolved due to different types with identical matching in 1 instance.
dDistribution of sequences: bla, blaSHV-1/blaSHV-28 (no further sequence discrimination possible), and bla in one instance each, insufficient discriminatory power in additional 3 instances.
eDistribution of sequences: bla (no further sequence discrimination possible), bla, and bla in one instance each, insufficient discriminatory power in another instance
fDistribution of sequences: bla in two instances, bla (no further sequence discrimination possible) and bla (no further sequence discrimination possible) in one instance each, insufficient discriminatory power in another instance.
Detection of carbapenemase genes in Enterobacteriaceae and nonfermentative, Gram-negative rod-shaped bacteria that did not test fully sensitive against carbapenems.
| Enterobacteriaceae from Libyan patients (n=2) | 2x | ||||||||||
| Enterobacteriaceae from Syrian patients (n=2) | 1 | 1 | |||||||||
*In 2 K. pneumoniae isolates.
°In the same E. cloacae isolate.
Resistance of isolated Enterobacteriaceae with resistance against 3rd generation methoxyimino cephalosporins (n=49) and/or carbapenems (n=6/49) as identified by VITEK-II.
| Enterobacteriaceae from Libyan patients at the Bundeswehr Hospitals of Hamburg and Westerstede (n=13) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Piperacillin / Tazobactam | Ceftazidime | Imipenem | Meropenem | Gentamicin | Ciprofloxacin | Levofloxacin | Tigecyclin | Fosfomycin | Nitrofurantoin | Cotrimoxazole | |
| R | 8 | 10 | 1 | 9 | 10 | 10 | 1 | 5 | 9 | ||
| I | 5 | 3 | 2 | 1 | 1 | 7 | 4 | ||||
| S | 0 | 11 | 11 | 4 | 2 | 3 | 5 | 13 | 4 | 4 | |
Resistance of isolated Acinetobacter baumannii complex as identified by VITEK-II.
| Piperacillin | Ceftazidime | Cefepime | Aztreonam | Imipenem | Meropenem | Gentamicin | Tobramycin | Ciprofloxacin | Colistin | Cotrimoxazole | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| R | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | |
| I | 1 | 1 | |||||||||
| S | 2 | ||||||||||
Resistance of isolated Pseudomonas aeruginosa as identified by VITEK-II.
| Piperacilli n | Ceftazidim e | Cefepim e | Aztreona m | Imipene m | Meropene m | Amikaci n | Gentamici n | Tobramyci n | Ciprofloxaci n | Colisti n | Cotrimoxazol e | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R | 3 | 3 | 2 | 1 | 2 | 2 | 2 | 2 | ||||
| I | 2 | 1 | ||||||||||
| S | 1 | 3 | 3 | 1 | 1 | 1 | 3 | 3 | ||||
Resistance of isolated MRSA as identified by VITEK-II.
| MRSA isolates from Syria | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Levoflo xacin | Moxifl oxacin | Genta micin | Clinda mycin | Erythro mycin | Cotrimo xazole | Tetrac ycline | Tigecy cline | Teicop lanin | Vanco mycin | Linez olid | Dapto mycin | Fosfo mycin | Fusi dic acid | Rifam picin | Mupir ocin | Nitrofur antoin | |
| R | 2 | 2 | 1 | 3 | |||||||||||||
| I | |||||||||||||||||
| S | 6 | 6 | 6 | 4 | 4 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 3 | 6 | 6 | 6 |
Figure 1.Clonal identities of E. cloacae strains. Light blue boxes = isolates from anonymously numbered Libyan (L) patients at the Bundeswehr Hospital Hamburg (HBG) with anonymous strain numbers in brackets. Dark blue box = isolate from an anonymously numbered Libyan (L) patient at the Bundeswehr Hospital Westerstede (WEST) with an anonymous strain number in brackets. Red box = isolate from an anonymously numbered Syrian (S) patient at the Bundeswehr Hospital Hamburg (HBG) with an anonymous strain number in brackets. Yellow boxes = isolates from anonymously numbered Syrian (S) patients at the Bundeswehr Hospital Westerstede (WEST) with anonymous strain numbers in brackets. Dotted arrows = clonally identical by rep-PCR but not by NGS typing. Continuous arrows = clonally identical by rep-PCR and by NGS typing
Figure 2.Clonal identities of A. baumannii strains. Red boxes = isolates from anonymously numbered Syrian (S) patients at the Bundeswehr Hospital Hamburg (HBG) with anonymous strain numbers in brackets. Yellow box = isolate from an anonymously numbered Syrian (S) patient at the Bundeswehr Hospital Westerstede (WEST) with an anonymous strain number in brackets. Dashed arrows = clonally identical by NGS typing but not by rep-PCR. Continuous arrows = clonally identical by rep-PCR and by NGS typing
Figure 3.Clonal identities of E. coli strains. Red boxes = isolates from anonymously numbered Syrian (S) patients at the Bundeswehr Hospital Hamburg (HBG) with anonymous strain numbers in brackets. Light blue box = isolate from an anonymously numbered Libyan (L) patient at the Bundeswehr Hospital Hamburg (HBG) with an anonymous strain number in brackets. Yellow boxes = isolates from anonymously numbered Syrian (S) patients at the Bundeswehr Hospital Westerstede (WEST) with anonymous strain numbers in brackets. Dotted arrows = clonally identical by rep-PCR but not by NGS typing. Dashed arrows = clonally identical by NGS typing but not by rep-PCR. Continuous arrows = clonally identical by rep-PCR and by NGS typing
Figure 4.Clonal identities of K. pneumoniae strains. Light blue boxes = isolates from anonymously numbered Libyan (L) patients at the Bundeswehr Hospital Hamburg (HBG) with anonymous strain numbers in brackets. Red boxes = isolates from anonymously numbered Syrian (S) patients at the Bundeswehr Hospital Hamburg (HBG) with anonymous strain numbers in brackets. Green boxes = isolates from an environmental screening of the rooms of Libyan patients at the Bundeswehr Hospital Hamburg (HBG, anonymous ward 2) with anonymous strain numbers in brackets. Dashed arrows = clonally identical by NGS typing but not by rep-PCR. Continuous arrows = clonally identical by rep-PCR and by NGS typing
Figure 5.Clonal identities of C. freundii strains. Yellow boxes = isolates from anonymously numbered Syrian (S) patients at the Bundeswehr Hospital Westerstede (WEST) with anonymous strain numbers in brackets. Continuous arrow = clonally identical by rep-PCR and by NGS typing
Figure 6.Clonal identities of R. planticola strains. Yellow boxes = isolates from anonymously numbered Syrian (S) patients at the Bundeswehr Hospital Westerstede (WEST) with anonymous strain numbers in brackets. Continuous arrow = clonally identical by rep-PCR and by NGS typing
Figure 7.Clonal identities of P. aeruginosa strains. Light blue box = isolate from an anonymously numbered Libyan (L) patient at the Bundeswehr Hospital Hamburg (HBG) with an anonymous strain number in brackets. Dark blue box = isolate from an anonymously numbered Libyan (L) patient at the Bundeswehr Hospital Westerstede (WEST) with an anonymous strain number in brackets. Green boxes = isolates from an environmental screening of the rooms of Libyan patients at the Bundeswehr Hospital Hamburg (HBG, anonymous ward 2) with anonymous strain numbers in brackets. Dashed arrows = clonally identical by NGS typing but not by rep-PCR
Resistance testing as determined by NGS with the ResFinder Software.
| ID and species | Phenotypic resistance by Vitek II (acronyms of antibiotics that were not tested sensitive) | Genotypic detection of resistance genes by NGS with low coverage* | Phenotypic resistance without detected genotypic correlate | Genotypic resistance without detected phenotypic correlate |
|---|---|---|---|---|
| 1 | PRL, TZP, CTX, CAZ, FEP, ATM, IPM, MEM, GC, NN, CIP, COT | execution failed | ||
| AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, TGC | execution failed | |||
| 3 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, TGC, NF, COT | fluoroquinolone, tetracycline, trimethoprim | none | |
| 4 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CIP, LEV, COT | execution failed | ||
| 5 | PRL, TZP, CAZ, ATM, CIP, COT | execution failed | ||
| 6. | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, COT | none | aminoglycoside | |
| 7 | PRL, TZP, CAZ, FEP, ATM, AK, GC, NN, CIP, COT | none | fosfomycin (not tested phenotypically) | |
| 8 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, NF | execution failed | ||
| 9 | PRL, TZP, CTX, CAZ, FEP, ATM, IPM, MEM, GC, NN, CIP, COT | execution failed | ||
| 10 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, TGC, NF, COT | execution failed | ||
| 11 | PRL, TZP, CAZ, FEP, ATM, AK, GC, NN, CIP, COT | execution failed | ||
| 12 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, IPM, MEM, GC, CIP, LEV, NF, COT | execution failed | ||
| 13 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, IPM, MEM, GC, CIP, LEV, TGC, NF | execution failed | ||
| 14 | AMP, SAM, TZP, CXM, CXMAX, CPD. CTX, CAZ, GC, CIP, LEV, TGC, NF, COT | execution failed | ||
| 15 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CIP, TGC, NF, COT | execution failed | ||
| 16 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, TGC, NF | execution failed | ||
| 17 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, COT | execution failed | ||
| 18 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CN, CIP, LEV, TGC, NF, COT | execution failed | ||
| 19 | ATM, COT | execution failed | ||
| 20 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, IMP, MEM, GC, CIP, LEV, TGC, NF, COT | execution failed | ||
| 21 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV | no sequence data | ||
| 26 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, IMP, MEM, GC, CIP, LEV, TGC, FOS, NF, COT | execution failed | ||
| 27 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, TGC, NF | no sequence data | ||
| 28 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, TGC, NF | execution failed | ||
| 29 | ATM, COT | trimethoprim | aminoglycoside, beta-lactam, fluoroquinolone, fosfomycin (not tested phenotypically) | |
| 30 | PRL, MEM, CIP, LEV, | execution failed | ||
| 31 | PRL, TZP, CTX, CAZ, FEP, ATM, IPM, MEM, GC, NN, CIP, COT | execution failed | ||
| 32 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, FOS, NF, COT | execution failed | ||
| 33 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ | execution failed | ||
| 36 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, TGC, FOS, NF, COT | fosfomycin, fluoroquinolone, nitrofurantoin | none | |
| 37 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV | execution failed | ||
| 38 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, COT | execution failed | ||
| 39 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, TGC, NF | execution failed | ||
| 40 | PRL, PZP, ATM, COT | sulfonamide, trimethoprim | aminoglycoside, fosfomycin | |
| 41 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CIP, LEV, TGC, FOS, NF, COT | fosfomycin | aminoglycoside | |
| 42 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CIP, LEV, TGC, NF, COT | tetracycline | aminoglycoside, fosfomycin | |
| 44 | no EUCAST breakpoints for VITEK available | |||
| 45 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CIP, LEV, COT | execution failed | ||
| 46 | no EUCAST breakpoints for VITEK available | |||
| 47 | PRL, CTX, CAZ, FEP, ATM, IPM, MEM, GC, NN, CIP, COT | sulphonamide | none | |
| 48 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, FOS, COT | none | tetracycline | |
| 49 | PRL, CTX, CAZ, FEP, ATM, IPM, MEM, GC, NN, CIP, COT | fluoroquinolone, sulphonamide, trimethoprim | tetracycline (not tested phenotypically) | |
| 50 | PRL, CTX, CAZ, FEP, ATM, IPM, MEM, GC, NN, CIP, COT | sulphonamide, trimethoprim, fluoroquinolone | tetracycline (not tested phenotypically) | |
| 51 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, COT | |||
| 52 | AMP, SAM, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, FOS | none | tetracycline | |
| 54 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, COT | execution failed | ||
| 55 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CIP, LEV, COT | |||
| 56 | PRL, CTX, CAZ, FEP, ATM, IPM, MEM, CIP | fluoroquinolone | aminoglycoside, tetracycline (not tested phenotypically) | |
| 57 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, TGC, FOS, NF, COT | execution failed | ||
| 59 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, TGC, NF | no resistance genes found | ||
| 60 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CIP, LEV, COT | no resistance genes found | ||
| 61 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CIP, LEV, COT | none | aminoglycoside, tetracycline | |
| 62 | PRL, CTX, CAZ, FEP, ATM, IPM, MEM, GC, NN, CIP, COT | |||
| 63 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CIP | no resistance genes found | ||
| 64 | PRL, CTX, CAZ, FEP, ATM, IPM, MEM, GC, NN, CIP | execution failed | ||
| 65 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ | beta-lactam | fluoroquinolone | |
| 66 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC | none | tetracycline | |
| 68 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CIP, LEV | fluoroquinolone | aminoglycoside | |
| 69 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, TGC, NF, COT | execution failed | ||
| 70 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, IPM, MEM, CIP, LEV, TGC, FOS, COT | no resistance genes found | ||
| 71 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, CIP, LEV, NF | execution failed | ||
| 72 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, COT | execution failed | ||
| 73 | PRL, CTX, CAZ, FEP, ATM, IPM, MEM, GC, NN, CIP | execution failed | ||
| 74 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ | execution failed | ||
| 75 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, COT | execution failed | ||
| 76 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV | execution failed | ||
| 77 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, NF, COT | execution failed | ||
| 78 | AMP, SAM, TZP, CXM, CXMAX, CPD, CTX, CAZ, GC, CIP, LEV, TGC, NF | execution failed |